MedTrace Logo

Efficacy, Tolerability and Safety of Azilect in Subjects With Progressive Supranuclear Palsy

NCT01187888 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2013-04-24

No results posted yet for this study

Summary

The purpose of this study is to determine whether rasagiline is effective in the treatment of Progressive Supranuclear Palsy (PSP), a rapidly progressing disease with a symptomatology similar to Parkinson's Disease. The major aim of this study is the limitation or halting of the process of neurodegeneration and influence postural instability.

Conditions

Interventions

DRUG

Rasagiline

tablet once daily 1 mg 1 year

DRUG

Sugar pill

tablet once daily one year

Sponsors & Collaborators

  • Teva Branded Pharmaceutical Products R&D, Inc.

    collaborator INDUSTRY

  • Ludwig-Maximilians - University of Munich

    collaborator OTHER

  • Prof. Dr. Stefan Lorenzl

    lead OTHER

Principal Investigators

  • Stefan Lorenzl, PD Dr. · Klinikum der Universität München (Hospital of the University of Munich)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2012-06-30
Completion
2012-06-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01187888 on ClinicalTrials.gov